DK1229047T3 - IL-1-receptor-fusionsproteiner anvendt som antagonister og fremgangsmåder til fremstilling og anvendelse - Google Patents

IL-1-receptor-fusionsproteiner anvendt som antagonister og fremgangsmåder til fremstilling og anvendelse

Info

Publication number
DK1229047T3
DK1229047T3 DK02007831T DK02007831T DK1229047T3 DK 1229047 T3 DK1229047 T3 DK 1229047T3 DK 02007831 T DK02007831 T DK 02007831T DK 02007831 T DK02007831 T DK 02007831T DK 1229047 T3 DK1229047 T3 DK 1229047T3
Authority
DK
Denmark
Prior art keywords
methods
antagonists
preparation
fusion proteins
proteins used
Prior art date
Application number
DK02007831T
Other languages
English (en)
Inventor
George D Yancopoulos
Neil Stahl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK1229047T3 publication Critical patent/DK1229047T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02007831T 1998-09-25 1999-09-22 IL-1-receptor-fusionsproteiner anvendt som antagonister og fremgangsmåder til fremstilling og anvendelse DK1229047T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10185898P 1998-09-25 1998-09-25
US09/313,942 US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using
EP99952942A EP1115876B1 (en) 1998-09-25 1999-09-22 Receptor based antagonists and methods of making and using

Publications (1)

Publication Number Publication Date
DK1229047T3 true DK1229047T3 (da) 2005-02-21

Family

ID=26798712

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02007831T DK1229047T3 (da) 1998-09-25 1999-09-22 IL-1-receptor-fusionsproteiner anvendt som antagonister og fremgangsmåder til fremstilling og anvendelse

Country Status (19)

Country Link
US (2) US6472179B2 (da)
EP (3) EP1115876B1 (da)
JP (1) JP3902728B2 (da)
CN (1) CN100345970C (da)
AT (2) ATE336583T1 (da)
AU (1) AU758970C (da)
BE (1) BE2010C021I2 (da)
CA (1) CA2345109C (da)
DE (3) DE69932832T2 (da)
DK (1) DK1229047T3 (da)
ES (2) ES2267300T3 (da)
FR (1) FR10C0025I2 (da)
HK (2) HK1045847B (da)
IL (2) IL142103A0 (da)
NO (2) NO329976B1 (da)
NZ (1) NZ510720A (da)
PL (1) PL201246B1 (da)
PT (1) PT1229047E (da)
WO (1) WO2000018932A2 (da)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ATE272114T1 (de) 1998-01-23 2004-08-15 Immunex Corp Rezeptoren für il-18
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1283851B1 (en) * 2000-05-26 2012-03-28 Immunex Corporation Use of il-4r antibodies and compositions thereof
CA2447632C (en) 2000-06-16 2011-08-02 Asterion Limited Fusion protein agonist comprising a growth hormone binding portion and an external domain of a growth hormone receptor
WO2002012345A2 (en) 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US6846520B2 (en) * 2002-01-17 2005-01-25 Canon Kabushiki Kaisha Epoxy resin composition, surface treatment method, liquid-jet recording head and liquid-jet recording apparatus
AU2003243189B2 (en) * 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
KR101329843B1 (ko) 2002-11-15 2013-11-14 젠맵 에이/에스 Ｃｄ25에 대한 인간 모노클로날 항체
US6919012B1 (en) 2003-03-25 2005-07-19 Olimex Group, Inc. Method of making a composite article comprising a ceramic coating
AU2004224122A1 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Improved Fc fusion proteins
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
EP1664114A1 (en) * 2003-06-11 2006-06-07 Wyeth Method for producing a polypeptide
DK3095793T3 (da) * 2003-07-28 2020-05-25 Genentech Inc Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
JP2007503820A (ja) * 2003-09-05 2007-03-01 ナショナル・リサーチ・カウンシル・オブ・カナダ 細胞レセプタードメインを含むコイルドコイル融合タンパク質
ATE548388T1 (de) 2003-11-07 2012-03-15 Immunex Corp An den interleukin-4-rezeptor bindende antikörper
JP2008504806A (ja) * 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用
MXPA06014126A (es) 2004-06-04 2007-07-18 Regeneron Pharma Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias.
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
JP4948410B2 (ja) * 2004-08-17 2012-06-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−１アンタゴニスト製剤
EP1630232B1 (en) * 2004-08-27 2008-07-02 CONARIS research institute AG Optimized nucleotide sequences encoding sgp130
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
PT2229956E (pt) * 2004-09-13 2013-07-31 Genzyme Corp Contruções multiméricas
RU2007117716A (ru) * 2004-10-12 2008-11-20 Ампротеин Корпорейшн (Us) Химерный белок
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
WO2006079169A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
PT1861116E (pt) 2005-03-25 2015-11-04 Regeneron Pharma Formulações de antagonista do vegf
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
RS54088B1 (en) 2005-07-25 2015-10-30 Emergent Products Development Seattle Llc B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US7889347B2 (en) 2005-11-21 2011-02-15 Plexera Llc Surface plasmon resonance spectrometer with an actuator driven angle scanning mechanism
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20180030264A (ko) 2005-11-23 2018-03-21 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
ES2352561T3 (es) 2006-06-30 2011-02-21 Conaris Research Institute Ag Dímeros de sgp 130fc mejorados.
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
CA2658786A1 (en) * 2006-07-28 2008-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
NZ575972A (en) * 2006-10-20 2011-01-28 Regeneron Pharma Use of il-1 antagonists to treat gout and pseudogout
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5272735B2 (ja) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 生物学的製剤
JP5237970B2 (ja) 2007-02-01 2013-07-17 アクセルロン ファーマ， インコーポレイテッド 乳癌を治療または予防するためのアクチビンＡｃｔＲＩＩａアンタゴニストおよび使用
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EP2120999B1 (en) 2007-02-09 2012-08-29 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists and use thereof in preventing or treating multiple myeloma
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
EP2140005B1 (en) 2007-03-19 2013-12-11 National Research Council of Canada Fusion proteins comprising two tgf-beta binding domains
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
EP2214703A1 (en) * 2007-10-31 2010-08-11 The Scripps Research Institute Combination therapy to treat persistent viral infections
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
CA2719924C (en) 2008-04-11 2017-10-03 Philip Tan Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PL3494986T3 (pl) 2008-08-14 2020-11-16 Acceleron Pharma Inc. Pułapki GDF
EP2326670A4 (en) * 2008-09-17 2014-04-16 Nat Res Council Canada HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
CN102245634B (zh) 2008-11-26 2014-10-08 安姆根有限公司 激活素iib受体多肽的变异体及其用途
EP3345921A1 (en) 2009-06-08 2018-07-11 Acceleron Pharma Inc. Use of anti-actriib antibodies for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
WO2012142391A1 (en) 2011-04-15 2012-10-18 Merck Patemt Gmbh Anti- il-1r1 inhibitors for use in cancer
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CA2859504A1 (en) 2011-12-19 2013-07-18 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
EP3308796B1 (en) 2012-11-02 2021-07-14 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
WO2014090800A1 (en) * 2012-12-10 2014-06-19 Vib Vzw Novel interleukin-33 inhibitors
EP2951205B1 (en) 2013-02-01 2021-08-11 Santa Maria Biotherapeutics, Inc. Anti-activin-a compounds for the treatment of ovarian cancer
EA033269B1 (ru) 2013-02-15 2019-09-30 Р-Фарм Интернешнл, Ооо (Общество С Ограниченной Ответственностью) СОСТАВ ИНГИБИТОРА ИНТЕРЛЕЙКИНА-1 БЕТА (IL-1β) И ЕГО ПРИМЕНЕНИЕ
AP2017009674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
MX2017000840A (es) 2014-07-18 2017-05-04 Sanofi Sa Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP6775513B2 (ja) 2014-12-01 2020-10-28 フェリング・ベー・フェー 選択的ｉｌ−６−トランス−シグナル伝達阻害剤の投与
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
MD4801C1 (ro) 2014-12-03 2022-10-31 Celgene Corporation Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
JP7240812B2 (ja) * 2015-05-12 2023-03-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多量体タンパク質の純度の決定
AU2016326449A1 (en) 2015-09-21 2018-03-22 Aptevo Research And Development Llc CD3 binding polypeptides
KR20190128618A (ko) 2016-09-27 2019-11-18 에피센트알엑스, 인코포레이티드 면역조정 융합 단백질
CA3059731A1 (en) * 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
JP2020536518A (ja) 2017-09-27 2020-12-17 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
AU2019231791B2 (en) 2018-03-09 2022-08-11 Agenus Inc. Anti-CD73 antibodies and methods of use thereof
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CN110950965B (zh) * 2018-09-26 2021-10-15 重庆精准生物技术有限公司 抗人cd123的嵌合抗原受体及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
AU651596B2 (en) * 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
ES2251009T3 (es) * 1990-06-28 2006-04-16 Sanofi-Aventis Deutschland Gmbh Proteinas de fusion con partes de inmunoglobulinas, su preparacion y uso.
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
EP0611302B1 (en) * 1991-10-15 2000-03-29 MULLARKEY, Michael F. Receptors for treating late phase inflammatory responses
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
EP0643719B1 (en) * 1992-03-09 1998-10-21 Ludwig Institute For Cancer Research Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
AU671116B2 (en) * 1992-03-30 1996-08-15 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US5747292A (en) * 1993-04-06 1998-05-05 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
WO1995006737A1 (en) * 1993-09-03 1995-03-09 Kenneth Francis Prendergast Glycophorin binding protein (gbp130) fusion compositions
CA2174098C (en) * 1993-10-14 2011-01-25 Douglas A. Melton Method of inducing and maintaining neuronal cells
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
IL114825A0 (en) * 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
WO1996011213A1 (en) 1994-10-07 1996-04-18 Amgen Boulder Inc. Dimeric il-4 inhibitors
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
US5837816A (en) * 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
WO1998002558A2 (en) * 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
ATE272114T1 (de) * 1998-01-23 2004-08-15 Immunex Corp Rezeptoren für il-18

Also Published As

Publication number Publication date
NZ510720A (en) 2003-11-28
EP1229047A3 (en) 2002-10-02
PT1229047E (pt) 2005-03-31
NO329976B1 (no) 2011-01-31
US20020164690A1 (en) 2002-11-07
HK1045847A1 (en) 2002-12-13
WO2000018932A3 (en) 2000-11-02
IL142103A (en) 2007-07-04
ES2267300T3 (es) 2007-03-01
AU758970C (en) 2007-05-03
EP1405915A1 (en) 2004-04-07
WO2000018932A2 (en) 2000-04-06
JP3902728B2 (ja) 2007-04-11
CN100345970C (zh) 2007-10-31
US20020012962A1 (en) 2002-01-31
CN1357049A (zh) 2002-07-03
AU6499499A (en) 2000-04-17
DE122010000023I2 (de) 2012-04-26
DE69932832D1 (de) 2006-09-28
ATE283365T1 (de) 2004-12-15
NO20011513L (no) 2001-05-25
NO2011003I1 (no) 2011-05-02
PL201246B1 (pl) 2009-03-31
JP2002525119A (ja) 2002-08-13
EP1229047A2 (en) 2002-08-07
DE69932832T2 (de) 2007-02-08
EP1115876A2 (en) 2001-07-18
IL142103A0 (en) 2002-03-10
HK1035377A1 (en) 2001-11-23
US6472179B2 (en) 2002-10-29
AU758970B2 (en) 2003-04-03
FR10C0025I1 (da) 2010-05-21
CA2345109A1 (en) 2000-04-06
EP1229047B1 (en) 2004-11-24
DE69922269T2 (de) 2005-12-01
EP1115876B1 (en) 2006-08-16
BE2010C021I2 (da) 2018-12-04
ES2233733T3 (es) 2005-06-16
NO20011513D0 (no) 2001-03-23
DE122010000023I1 (de) 2012-04-26
FR10C0025I2 (fr) 2011-04-01
DE69922269D1 (de) 2004-12-30
PL348529A1 (en) 2002-06-03
CA2345109C (en) 2012-12-18
ATE336583T1 (de) 2006-09-15
NO2011003I2 (da) 2011-04-11
HK1045847B (zh) 2005-03-24
WO2000018932A9 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
DK1229047T3 (da) IL-1-receptor-fusionsproteiner anvendt som antagonister og fremgangsmåder til fremstilling og anvendelse
DK1572967T3 (da) IL-1-receptorbaserede antagonister og fremgangsmåder til fremstilling og anvendelse deraf
DK1012274T3 (da) Dödsdomæneholdig receptor-4 (DR4: dödsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
ATE318905T1 (de) Homologe des tie-rezeptortyrosinekinase liganden
IS2786B (is) Prótín sem bindast viðtaka Nogo
EA200500330A1 (ru) Антагонисты nogo рецепторов
ATE490323T1 (de) Adiponektin-rezeptor und dafür kodierendes gen
BRPI0413426A (pt) antagonistas de receptor novo
ATE390482T1 (de) Interleukin-1 hy2. mittel und verfahren
DK1009817T3 (da) RTD-receptor
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
ATE470858T1 (de) Opiatrezeptoren
DE60236143D1 (de) Gewebe transglutaminase
EP0965594A3 (en) Nef-attachable protein, DNA encoding the protein and a monoclonal antibody against said protein
SE0002364D0 (sv) Growth Factors